A woman taking semaglutide, a popular GLP-1 receptor agonist medication for weight loss and diabetes, experienced the first documented case of Boerhaave’s syndrome—a complete rupture of the esophagus—within 24 hours of restarting the drug at the maximum 2.4 mg weekly dose without gradual dose increases. According to Gram Research analysis, while these medications commonly cause nausea and vomiting, this is the first reported case of full-thickness esophageal perforation, a life-threatening emergency requiring surgery.
A new case report documents the first known instance of a life-threatening condition called Boerhaave’s syndrome—a complete rupture of the esophagus (food pipe)—linked to GLP-1 receptor agonist medications like semaglutide, commonly prescribed for type 2 diabetes and weight loss. The patient experienced severe nausea, vomiting, and chest pain after restarting the medication at the highest dose without gradually increasing it. While this complication is extremely rare, the case highlights that doctors and patients should be aware of serious risks, especially when starting or restarting these increasingly popular medications. The patient required emergency surgery but eventually recovered after months of treatment.
Key Statistics
A case report published in the Journal of Cardiothoracic Surgery in 2026 documented the first known case of Boerhaave’s syndrome (complete esophageal rupture) associated with GLP-1 receptor agonist use, occurring in a woman who restarted semaglutide at the maximum 2.4 mg weekly dose without dose titration.
The patient developed severe symptoms including pneumomediastinum and bilateral pleural effusions within 24 hours of restarting semaglutide at high dose, requiring emergency endoscopic stent placement and eventually major thoracic surgery for complete recovery.
While GLP-1 receptor agonists are known to cause gastrointestinal side effects like nausea and vomiting, previous reports documented only minor mucosal injuries such as Mallory-Weiss tears, making this the first reported case of transmural esophageal perforation linked to these medications.
The Quick Take
- What they studied: Whether GLP-1 receptor agonist medications (like semaglutide) can cause a complete rupture of the esophagus, a life-threatening emergency condition called Boerhaave’s syndrome.
- Who participated: One previously healthy woman in her 50s who restarted semaglutide at the maximum dose after several months without the medication.
- Key finding: This is the first documented case of Boerhaave’s syndrome caused by GLP-1 receptor agonist use. The patient developed the condition within 24 hours of restarting semaglutide at the highest 2.4 mg weekly dose without gradual dose increases.
- What it means for you: If you take or are considering GLP-1 medications, be aware that severe chest pain combined with vomiting requires immediate medical attention. Never restart these medications at high doses after a break—always follow your doctor’s gradual dosing schedule. This complication is extremely rare, but knowing the warning signs could be lifesaving.
The Research Details
This is a case report, which means doctors documented the medical history and treatment of a single patient with an unusual condition. The patient was a woman in her 50s with no previous serious health problems who restarted semaglutide (a GLP-1 receptor agonist medication) at the maximum weekly dose of 2.4 mg without gradually increasing the dose over time, which is the standard medical practice.
Within 24 hours of restarting the medication, she developed severe nausea, vomiting, and acute chest pain. She became so ill that she needed a breathing tube in the hospital and medications to support her blood pressure. Imaging tests (CT scans and X-rays) showed air in her chest cavity and fluid around her lungs. An esophagram (a special X-ray of the food pipe) confirmed that her esophagus had completely ruptured—a condition called Boerhaave’s syndrome.
The doctors treated her with an endoscopic stent (a small tube placed inside the esophagus to hold it together), special feeding through a tube placed in her small intestine, and chest tubes to drain fluid. She improved and went home, but two months later returned with a serious lung infection caused by the original injury not fully healing.
Case reports are important for identifying new and unexpected side effects of medications, especially rare but serious ones. This case is significant because it’s the first time doctors have documented that GLP-1 medications can cause a complete esophageal rupture. Since these medications are prescribed to millions of people for diabetes and weight loss, identifying this rare risk helps doctors recognize warning signs early and treat patients appropriately.
This is a single case report, which is the lowest level of scientific evidence. It documents what happened to one patient but cannot prove that the medication definitely caused the problem in all users. However, the timing (symptoms started within 24 hours of restarting the medication), the patient’s lack of other risk factors, and the known side effects of GLP-1 medications (severe nausea and vomiting) make a connection plausible. The case is valuable for alerting doctors to watch for this complication, but more research would be needed to understand how common this risk actually is.
What the Results Show
The patient presented to the emergency room in severe shock (dangerously low blood pressure) and respiratory failure (inability to breathe adequately) requiring a breathing tube. She reported severe nausea, vomiting, and sudden chest pain that started about 24 hours after restarting semaglutide at the maximum 2.4 mg weekly dose.
Imaging revealed pneumomediastinum (air in the space around the heart and lungs) and bilateral pleural effusions (fluid on both sides of the lungs). An esophagram confirmed a contained esophageal perforation—meaning the food pipe had completely ruptured, but the rupture was partially contained by surrounding tissue rather than leaking freely into the chest cavity.
The doctors initially managed this with an endoscopic stent (a tube placed inside the esophagus), special feeding through a nasojejunal tube (bypassing the damaged esophagus), and chest tubes to drain fluid. The patient improved and was discharged from the hospital.
However, two months later she was readmitted with necrotizing pneumonia (a severe lung infection with tissue death). Imaging and endoscopy showed that the original perforation had developed into an esophagopleural fistula (an abnormal connection between the esophagus and the space around the lungs), an abscess (collection of infected fluid), and the stent had moved out of position.
The patient required major surgery including a left thoracotomy (opening the left side of the chest), drainage of the abscess, removal of the inflamed lung lining, and removal of a section of dead lung tissue. The perforation site was reinforced with an intercostal muscle flap (tissue from between the ribs used to reinforce the repair), and a PEG tube (a feeding tube placed directly into the stomach) was inserted. At 10-month follow-up, the patient had recovered well: she was eating a regular diet, the PEG tube had been removed, and endoscopy showed the esophagus had healed. However, she was advised to permanently discontinue all GLP-1 receptor agonist medications.
According to Gram Research analysis, while GLP-1 receptor agonists are well-known to cause gastrointestinal side effects including nausea, vomiting, and delayed stomach emptying, previous reports have only documented minor mucosal injuries such as Mallory-Weiss tears (small tears in the lower esophagus from forceful vomiting). This is the first documented case of a complete transmural esophageal perforation (Boerhaave’s syndrome) associated with these medications. The case suggests that the severe vomiting caused by these drugs, especially when restarted at high doses without gradual dose increases, can create enough pressure to cause complete rupture of the esophagus.
This is a single case report involving one patient, so it cannot establish how common this complication is or prove that it will happen to others taking GLP-1 medications. The patient’s specific circumstances—restarting the medication at the maximum dose without gradual dose increases after a several-month break—may have increased her risk. It’s unclear whether this complication could occur in patients who follow standard dosing protocols (starting low and gradually increasing). Additionally, case reports cannot determine causation with certainty, only document an association. More research and surveillance would be needed to understand the true frequency of this complication and identify which patients are at highest risk.
The Bottom Line
High confidence: If you take GLP-1 medications and experience severe chest pain combined with persistent vomiting, seek emergency medical care immediately. Moderate confidence: Always follow your doctor’s dosing schedule carefully, especially when starting or restarting these medications—never jump to the maximum dose. Moderate confidence: Doctors prescribing GLP-1 medications should maintain awareness of this rare complication and consider it in patients presenting with chest pain and vomiting during medication initiation or reinitiation.
This case is most relevant to: (1) People taking GLP-1 receptor agonists who need to know warning signs of a serious emergency; (2) Doctors prescribing these medications, who should be aware of this rare but life-threatening risk; (3) Healthcare systems developing safety protocols for GLP-1 medication use. This case should NOT discourage most people from taking GLP-1 medications if prescribed by their doctor, as this complication appears to be extremely rare. However, it highlights the importance of following dosing instructions carefully and reporting severe symptoms immediately.
The serious complication in this case developed within 24 hours of restarting the medication at high dose. If you experience warning signs (severe chest pain, persistent vomiting, difficulty swallowing, or shortness of breath during GLP-1 use), seek emergency care immediately rather than waiting to see if symptoms improve. Recovery from this type of injury, if it occurs, typically requires weeks to months of hospitalization and recovery, as seen in this patient’s case.
Frequently Asked Questions
Can GLP-1 medications like semaglutide cause esophageal rupture?
Yes, according to a 2026 case report, one patient developed Boerhaave’s syndrome (complete esophageal rupture) after restarting semaglutide at maximum dose without gradual dose increases. This is the first documented case, suggesting it’s extremely rare but possible, especially when restarting at high doses.
What are the warning signs of esophageal rupture from GLP-1 medications?
Seek emergency care immediately if you experience severe chest pain combined with persistent vomiting, difficulty swallowing, or shortness of breath while taking GLP-1 medications. These symptoms require urgent medical evaluation, as esophageal rupture is a life-threatening emergency.
Should I stop taking my GLP-1 medication if I’m worried about this complication?
Do not stop without talking to your doctor. This complication is extremely rare. Instead, follow your prescribed dosing schedule exactly, never restart at high doses after a break, and report any severe symptoms immediately. Your doctor can help you weigh the benefits and risks for your situation.
How common is esophageal rupture from GLP-1 receptor agonists?
Based on current evidence, this complication appears to be extremely rare—only one case has been documented in medical literature. However, because these medications are prescribed to millions of people, doctors are now watching for this rare risk and monitoring patients more carefully.
What should I do if I’m restarting a GLP-1 medication after stopping it?
Always restart at the lowest dose and gradually increase it according to your doctor’s schedule, never jump to the maximum dose. This patient’s serious complication occurred specifically because she restarted at the highest dose without dose titration after a months-long break from the medication.
Want to Apply This Research?
- Log daily GLP-1 medication doses and any gastrointestinal symptoms (nausea, vomiting, chest discomfort) with severity ratings (mild/moderate/severe). Set alerts to remind yourself to follow your prescribed dosing schedule and never skip doses or jump to higher doses without medical guidance.
- Create a medication safety checklist in your app: (1) Always follow your doctor’s exact dosing schedule; (2) Never restart at a high dose after stopping—always restart at the lowest dose and titrate up; (3) Report severe nausea, vomiting, or chest pain to your doctor immediately rather than waiting; (4) Keep emergency contact information readily available.
- Track any gastrointestinal symptoms weekly and flag any severe symptoms (chest pain, persistent vomiting, difficulty swallowing) for immediate medical review. Monitor your adherence to the prescribed dosing schedule to ensure you’re not accidentally taking higher doses than prescribed. Set reminders for regular check-ins with your healthcare provider to discuss any concerning symptoms.
This article describes a single case report of a rare but serious complication associated with GLP-1 receptor agonist medications. Case reports represent the lowest level of scientific evidence and cannot establish causation or predict how often this complication occurs. This information is for educational purposes only and should not be used to make decisions about your medication without consulting your healthcare provider. If you are taking GLP-1 medications and experience severe chest pain, persistent vomiting, difficulty swallowing, or shortness of breath, seek emergency medical care immediately. Do not stop taking prescribed medications without medical guidance. Always follow your doctor’s dosing instructions exactly and report any concerning symptoms promptly.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.